Increased frailty of patients with heart failure with preserved ejection fraction should have no bearing on whether those patients receive sacubitril/valsartan, according to results of a data analysis.
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction-agnostic management approach.
A new study found that the relationship between early LV recovery after TAVR and improved mortality was robust and durable, with surprising differences between the sexes.
Results of a new TOPCAT analysis point to the need to determine the optimal salt restriction range for patients with heart failure with preserved ejection fraction.